1332492-85-9

Upstream product

• 239079-89-1 1-bromo-2-methyl-3-nitro-5-(trifluoromethyl)benzene 
• 1332492-84-8 2-methyl-3-nitro-5-(trifluoromethyl)aniline 
• 955978-78-6 2-methyl-1,3-dinitro-5-(trifluoromethyl)benzene 

Downstream Products

• 1268264-10-3 Zgwatinib 
• 1332492-92-8 5-bromo-3-(4-benzylpiperazin-1-yl)-7-(trifluoromethyl)quinoline 
• 1332492-93-9 5-bromo-3-(4-phenylpiperazin-1-yl)-7-(trifluoromethyl)quinoline 
• 1332492-86-0 2-amino-6-bromo-4-(trifluoromethyl)benzaldehyde 
• 1332493-07-8 5-bromo-3-(4-methylpiperazin-1-yl)-2-phenyl-7-(trifluoromethyl)quinoline 
• 1332493-09-0 1,7-dibromo-3,9-bis(trifluoromethyl)-5,6,11,12-tetrahydro-6,12-epoxydibenzo[b,f][1,5]diazocine 
• 1332493-16-9 3-(4-methylpiperazin-1-yl)-N-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-7-(trifluoromethyl)quinolin-5-amine 

Relevant academic research and scientific papers

Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: Key precursors to potent c-Met inhibitors

An effective one-pot synthesis of quinolines bearing diverse C3-piperazinyl functions was developed by using a modified Friedlaender's protocol. The method not only enables the synthesis of our early reported c-Met inhibitor on a large scale, but also provides a way to generate novel multi-substituted quinolines for further structure-activity relationship (SAR) study.